Ipilimumab

WikiDoc Resources for Ipilimumab
Articles
Most recent articles on Ipilimumab Most cited articles on Ipilimumab Review articles on Ipilimumab Articles on Ipilimumab in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ipilimumab Images of Ipilimumab Photos of Ipilimumab Podcasts & MP3s on Ipilimumab Videos on Ipilimumab
Evidence Based Medicine
Cochrane Collaboration on Ipilimumab Bandolier on Ipilimumab TRIP on Ipilimumab
Clinical Trials
Ongoing Trials on Ipilimumab at Clinical Trials.gov Trial results on Ipilimumab Clinical Trials on Ipilimumab at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ipilimumab NICE Guidance on Ipilimumab NHS PRODIGY Guidance FDA on Ipilimumab CDC on Ipilimumab
Books
Books on Ipilimumab
News
Ipilimumab in the news Be alerted to news on Ipilimumab News trends on Ipilimumab
Commentary
Blogs on Ipilimumab
Definitions
Definitions of Ipilimumab
Patient Resources / Community
Patient resources on Ipilimumab Discussion groups on Ipilimumab Patient Handouts on Ipilimumab Directions to Hospitals Treating Ipilimumab Risk calculators and risk factors for Ipilimumab
Healthcare Provider Resources
Symptoms of Ipilimumab Causes & Risk Factors for Ipilimumab Diagnostic studies for Ipilimumab Treatment of Ipilimumab
Continuing Medical Education (CME)
CME Programs on Ipilimumab
International
Ipilimumab en Espanol Ipilimumab en Francais
Business
Ipilimumab in the Marketplace Patents on Ipilimumab
Experimental / Informatics
List of terms related to Ipilimumab

Overview

Ipilimumab (also known as MDX-010) is a human monoclonal antibody being developed by Bristol-Myers Squibb and Medarex. It is intended to be used as a drug to activate the immune system. Ipilimumab is undergoing clinical trials for the treatment of melanoma.

Ipilimumab is a fully human antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), a molecule on T-cells that is believed to play a critical role in regulating natural immune responses. The absence or presence of CTLA-4 can augment or suppress the immune system's T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining an active immune response in its attack on cancer cells.

As of October 2007 there are two fully human anti CTLA-4 [1] monoclonal antibodies in advanced clinical trials. Ipilimumab, which is an IgG1 isotype, and Tremelimumab (from Pfizer) which is an IgG2 isotype.

References

Template:Immunosuppressants Template:Humanmonoclonals Template:WH Template:WikiDoc Sources